Cardiac AI: The $14.8 Billion Shift to Multi-Condition Prevention
The landscape of cardiovascular artificial intelligence is undergoing a profound transformation, shifting from an era dominated by single-disease…
Cardiac AI Revenue: What iRhythm and HeartFlow Reveal
The landscape of cardiovascular artificial intelligence (AI) is rapidly evolving, with significant financial benchmarks emerging that offer critical…
Cardiac AI Exits: What Drives Billion Dollar Valuations?
The landscape of cardiac AI is rapidly evolving, marked by significant M&A activity that offers critical insights into…
HeartFlow’s Billion Dollar IPO: Clinical Evidence Driving Cardiac AI Valuation
The recent trajectory of HeartFlow, particularly its substantial capital raise and a deep evidentiary base, compels a rigorous…
iRhythm’s $747M: Cardiac AI Dominance & Investor Playbook
The landscape of cardiac AI monitoring diagnostics is witnessing a significant inflection point, where technological innovation meets stringent…
HeartFlow’s 625+ Papers: The Billion Dollar Evidence Moat
The valuation of AI in healthcare often orbits a singular, undeniable truth: clinical evidence is the ultimate de-risking…
Biofourmis, Oura: Investing in Always-On Cardiac AI Surveillance
The landscape of cardiac monitoring is undergoing a profound transformation, shifting from a reactive, episodic paradigm to one…
Viz.ai’s Billion Dollar Flight: Cracking Cardiac AI’s Unicorn Code
The valuation of Viz.ai at $1.2 billion USD represents a critical inflection point in the health AI landscape,…